SEC Form 4 · accession 0001562180-18-001641
REGENXBIO Inc. · RGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curran Simpson
Officer — SVP, Technical Operations
Period of report
Mar 13, 2018
Accepted (ET)
Mar 15, 2018 · 4:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590877
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 13, 2018 | M | 25,000 | $22.00 | A | 64,500 | D | |
| Common Stock | Mar 13, 2018 | S | 25,000 | $33.00 | D | 39,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $22.00 | Mar 13, 2018 | M | 25,000 | D | — | Aug 30, 2025 | Common Stock | 25,000 | 155,500 | D |
Explanation of responses
- F1The previously granted option, representing a right to purchase a total of 230,500 shares, became exercisable as follows: 25% of the shares subject to this option vested on August 31, 2016, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.